1.Comparison of Pancreatic Function after Pylorus Preserving Pancreatoduodenectomy according to the Pancreatoenterostomy.
Jin Young JANG ; Sun Whe KIM ; Sangjae PARK ; Yong Hyun PARK
Journal of the Korean Surgical Society 2000;58(1):94-101
BACKGROUND: Since the introduction of the Whipple procedure, it has been the standard treatment method for periampullary carcinomas. However, since the pancreatoduodenectomy has high operative morbidity and mortality, numerous modifications of the pancreatoduodenectomy have been developed to reduce the operative risk. Among the modifications of the pancreatoduodenectomy, the pancreatogastros tomy was developed to reduce pancreatic leakage, which is the most serious complication after a pancreatoduodenectomy. Many favorable data about the pancreatogastrostomy have been published recently. However, some surgeons are reluctant to do a pancreatogastrostomy for fear of early remnant pancreatic insufficiency due to reflux of gastric juice. For that reason, we compare the functional aspects of a pancreatoduodenectomy between a pancreatojejunostomy (P-J) and a pancreatogastrostomy (P-G). METHODS: We studied 35 patients who underwent a pylorus-preserving pancreatoduodenectomy (PPPD) with a diagnosis of a periampullary carcinoma (n=34) or pancreatitis (n=1) at Seoul National University Hospital between 1994 and 1997 and who lived without recurrence for over 1 year. The mean age was 57 year, and the sex ratio was 20:15. Among them, 20 patients received a pancreatojejunostomy; the others received a pancreatogastrostomy. To compare the two groups, we analyzed (1) general nutritional status, (2) gastrointestinal (GI) symptoms and pancreatic exocrine function by measuring fecal elastase, and (3) pancreatic endocrine function by using the oral glucose tolerance test (GTT). RESULTS: After a PPPD, the body weight was decreased in both groups compared to that of the preoperative healthy state, but there was no difference between two groups. Also, no statistical difference could be found in triceps skin-fold thickness and serum protein and albumin and postoperative gastrointestinal symptoms except steatorrhea. There were 4 mild and 15 severe pancreatic exocrine insufficiencies in P-J patients, but all P-G patients showed severe pancreatic insufficiency on the stool elastase test. Excluding preoperative diabetes patients, 44% (7/16) of the P-J patients had an abnormal GTT after the operation, but 75% (9/12) of the P-G patients had an abnormal GTT (p=0.114). CONCLUSION: Exocrine and endocrine pancreatic insufficiencies developed after a PPPD, but did not induce the general malnutrition. A P-G had more deterioration of the pancreatic function than a P-J did. Thus, we must consider the general nutritional status, as well as the risk of pancreatic leakage, in the determination of pancreatoenteric anastomosis.
Body Weight
;
Diagnosis
;
Exocrine Pancreatic Insufficiency
;
Gastric Juice
;
Glucose Tolerance Test
;
Humans
;
Malnutrition
;
Mortality
;
Nutritional Status
;
Pancreatic Elastase
;
Pancreaticoduodenectomy*
;
Pancreaticojejunostomy
;
Pancreatitis
;
Pylorus*
;
Recurrence
;
Seoul
;
Sex Ratio
;
Steatorrhea
2.Pancreatic Head Resection with Segmental Duodenectomy.
Sun Whe KIM ; Jin Young JANG ; Sangjae PARK ; Youn Chan PARK ; Yong Hyun PARK
Journal of the Korean Surgical Society 2000;59(4):519-525
PURPOSE: Duodenum-preserving resection of the head of the pancreas (DPRHP) requires meticulous dissection to preserve vascular circulation to the parapapillary area and has high risks for ischemia of these organs and associated complications. Pancreatic head resection with a segmental duodenectomy (PHRSD) is introduced to overcome technical difficulty and high risk. METHODS: A PHRSD was performed in 4 patients, one each with duodenal mucosa cancer, intraductal an papillary mucinous neoplasm of the pancreas, a villotubular adenoma of the papilla, and a serous cystadenoma of the pancreas. A bilateral subcostal incision was used for the laparotomy. By using Kocher's maneuver and dividing the adjacent ligament, we achieved full mobilization of the duodenum with the pancreas head, and confirmed a pathologic lesion. The superior pancreatiocoduodenal arteries were ligated and divided at the root with preservation of the gastroduodenal and the right gastroepiploic arteries. The anterior inferior pancreaticoduodenal artery was also preserved. The pancreatic head was resected using a 3- to 5-cm segmental duodenectomy at level 6 cm below the pyloric ring. After resection, reconstruction was performed using a pancreaticogastrostomy, duodenoduodenostomy, choledochoduodenostomy. RESULTS: No transfusions were required, and the mean operation time was 357 minutes. After this operation, no serious complications were developed. Minor pancreatic leakage developed in one case and was easily cured by conservative management. All patients were followed up without any clinical problems till now. CONCLUSION: A PHRSD can be recommended for the management of benign or low-grade malignant lesions of the pancreatic head and can also be used for the treatment of early cancer or polypoid lesions, which cannot be removed by using endoscopy, located in the duodenal second portion or the papilla.
Adenoma
;
Arteries
;
Choledochostomy
;
Cystadenoma, Serous
;
Duodenum
;
Endoscopy
;
Gastroepiploic Artery
;
Head*
;
Humans
;
Ischemia
;
Laparotomy
;
Ligaments
;
Mucins
;
Mucous Membrane
;
Pancreas
3.Analysis of Long-term Survivors after Pancreatoduodenectomy in the Patients with Pancreatic Cancer.
Jin Young JANG ; Sun Whe KIM ; Woo Ho KIM ; Hye Seung LEE ; Sangjae PARK ; Yoon Chan PARK ; Kuhn Uk LEE ; Yong Hyun PARK
Journal of the Korean Surgical Society 2001;60(1):89-96
PURPOSE: Pancreatic ductal adenocarcinoma is known to be very dismal. Although some publications reported marked improved survival data after surgical resection recently, many clinicians have pessimistic views on the treatment of pancreatic cancer. So we set the objectives of this study to evaluate the clinical results of pancreatoduodenectomy in pancreatic cancer and investigate what constitutes long term survival after pancreatoduodenectomy for pancreatic cancer. METHODS: We analyzed 286 patients with pancreatic head ductal adenocarcinoma hospitalized in Seoul National University Hospital between 1985 and 1995, retrospectively. We excluded the patients with cystic pancreatic tumor and solid pseudo-papillary tumor in this study. Of them, 67 patients received pancreatoduodenectomy. We re-reviewed the histologic specimens of resected cases and tried to find clinico- pathological features in long-term survivors after pancreatoduodenectomy. RESULTS: Median survival of total patients with pancreatic head cancer was 8 months. Significant survival difference could be found between resected cases (15 months) and non-resected cases (6 months) (p<0.001). Of the patients who underwent pancreatoduodenectomy, there were nine patients who survived more than three years. In the patients who underwent pancreatoduodenectomy, depth of invasion, lymph node metastasis, UICC stage, CEA level, adjuvant chemotherapy were the prognostic factors. After histologic re-review in the long-term survivors, there were only 4 typical ductal adenocarcinoma, and 2 cases of variant ductal adenocarcinoma (mucinous noncystic adenocarcinoma, undifferentiated adenocarcinoma), the others were re-diagnosed with bile duct cancer, papillary mucinous carcinoma, and pancreatoblastoma. When we excluded the patients with non ductal adenocarcinoma according to the pathologic review, the median survival of the patients with pancreatoduodenectomy (n=64) decreased (14 months). CONCLUSION: Only the 2% of all the pancreatic cancer and 11% of the resected cases could be considered as 'cure'. In the long-term survivors, there were various types of pathology associated with good prognosis, so typical ductal adenocarcinoma of pancreas would have poorer prognosis than expected. Careful pathologic review must be preceded in the analyzing the survival data.
Adenocarcinoma
;
Adenocarcinoma, Mucinous
;
Bile Duct Neoplasms
;
Chemotherapy, Adjuvant
;
Head
;
Head and Neck Neoplasms
;
Humans
;
Lymph Nodes
;
Neoplasm Metastasis
;
Pancreas
;
Pancreatic Ducts
;
Pancreatic Neoplasms*
;
Pancreaticoduodenectomy*
;
Pathology
;
Prognosis
;
Retrospective Studies
;
Seoul
;
Survivors*
4.Ginsenoside Rb1 Attenuates TGF-β1-Induced MUC4/5AC Expression and Epithelial-Mesenchymal Transition in Human Airway Epithelial Cells
Tae Yeong CHOI ; Joon-Hee KIM ; Sooyeon JO ; Sangjae LEE ; Hyung-Gyun NA ; Yoon Seok CHOI ; Si-Youn SONG ; Yong-Dae KIM ; Chang Hoon BAE
Korean Journal of Otolaryngology - Head and Neck Surgery 2021;64(4):232-239
Background and Objectives:
Ginsenoside Rb1 is the main metabolite of Panax ginseng. It is known to have many beneficial properties including anti-inflammatory, antitumoral and antioxidant effects. However, the therapeutic effects of ginenoside Rb1 on inflammatory airway diseases have not been elucidated. Therefore, we investigated the effects of ginsenoside Rb1 on the TGF-β1-induced mucin gene expression and epithelial-mesenchymal transition (EMT) in human airway epithelial cells.Materials and Method We evaluated the effects of ginsenoside Rb1 on the changes of MUC4, MUC5AC, occludin, claudin 4, claudin 18, neural (N)-cadherin, and epithelial (E)-cadherin expression by TGF-β1 in NCI-H292 cells using reverse, real-time polymerase chain reaction, enzyme-linked immunosorbent assay, and western blot.
Results:
TGF-β1 significantly increased MUC4/5AC expression. Rb1 inhibited TGF-β1- induced MUC4/5AC expression. In addition, TGF-β1 significantly attenuated occludin, claudin 18, and E-cadherin expressions but induced claudin 4 and N-cadherin expressions. On the other hand, Rb1 reversed changes in the TGF-β1- mediated expressions of cell junction molecules.
Conclusion
These results suggest that ginsenoside Rb1 attenuates TGF-β1-induced MUC4/5AC expressions and EMT in the human airway epithelial cells. These findings are important data demonstrating the potential of ginsenoside Rb1 as a therapeutic agent for inflammatory airway diseases.
5.Peroxiredoxin 2 Inhibits Lipopolysaccharide Induced Mucin Expression and Reactive Oxygen Species Production in Human Airway Epithelial Cells
Joon-Hee KIM ; Sooyeon JO ; Sangjae LEE ; Gi Moon YOO ; Hyung Gyun NA ; Yoon Seok CHOI ; Chang Hoon BAE ; Si-Youn SONG ; Yong-Dae KIM
Korean Journal of Otolaryngology - Head and Neck Surgery 2021;64(12):887-895
Background and Objectives:
Peroxiredoxin (Prx) is an antioxidant enzyme involved in signaling pathway. Prx2 is the most abundant in mammalian gray matter neurons and has protective role under oxidative stress. MUC5AC and MUC5B are typical mucin genes in human airway epithelial cells. Even if free radicals play a key role in chronic respiratory inflammatory diseases, the effects of the Prx2 on mucin expression and oxidative stress are not clearly known. The purpose of this study is to investigate the effect of Prx2 on lipopolysaccharide (LPS)-induced MUC5AC/5B expression and reactive oxygen species (ROS) in human airway epithelial cells.Subjects and Method In NCI-H292 cells and human nasal epithelial cells, the effects of Prx2 on LPS-induced MUC5AC/5B expression and ROS production were investigated using reverse transcriptase-polymerase chain reaction, real-time polymerase chain reaction, enzyme linked immunosorbent assay (ELISA) and flow cytometry analysis.
Results:
MUC5AC, MUC5B mRNA expression and protein production were increased by LPS. ROS production was also increased by LPS. Prx2 suppressed the LPS-induced MUC5AC mRNA expression and protein production as well as ROS production. However, Prx2 did not inhibit MUC5B mRNA expression and protein production. N-acetylcysteine, diphenyleneiodonium, and apocynin also inhibited LPS-induced ROS production.
Conclusion
These results may show that Prx2 suppresses LPS-induced MUC5AC expression via ROS in human airway epithelial cells.
6.Effects of GV1001 on Language Dysfunction in Patients With Moderate-to-Severe Alzheimer’s Disease: Post Hoc Analysis of Severe Impairment Battery Subscales
Hyuk Sung KWON ; Seong-Ho KOH ; Seong Hye CHOI ; Jee Hyang JEONG ; Hae Ri NA ; Chan Nyoung LEE ; YoungSoon YANG ; Ae Young LEE ; Jae-Hong LEE ; Kyung Won PARK ; Hyun Jeong HAN ; Byeong C. KIM ; Jinse PARK ; Jee-Young LEE ; Kyu-Yong LEE ; Sangjae KIM
Dementia and Neurocognitive Disorders 2023;22(3):100-108
Background:
and Purpose: The efficacy and safety of GV1001 have been demonstrated in patients with moderate-to-severe Alzheimer’s disease (AD). In this study, we aimed to further demonstrate the effectiveness of GV1001 using subscales of the Severe Impairment Battery (SIB), which is a validated measure to assess cognitive function in patients with moderate-tosevere AD.
Methods:
We performed a post hoc analysis of data from a 6 month, multicenter, phase 2, randomized, double-blind, placebo-controlled trial with GV1001 (ClinicalTrials.gov, NCT03184467). Patients were randomized to receive either GV1001 or a placebo for 24 weeks. In the current study, nine subscales of SIB—social interaction, memory, orientation, language, attention, praxis, visuospatial ability, construction, and orientation to name— were compared between the treatment (GV1001 1.12 mg) and placebo groups at weeks 12 and 24. The safety endpoints for these patients were also determined based on adverse events.
Results:
In addition to the considerable beneficial effect of GV1001 on the SIB total score, GV1001 1.12 mg showed the most significant effect on language function at 24 weeks compared to placebo in both the full analysis set (FAS) and per-protocol set (PPS) (p=0.017 and p=0.011, respectively). The rate of adverse events did not differ significantly between the 2 groups.
Conclusions
Patients with moderate-to-severe AD receiving GV1001 had greater language benefits than those receiving placebo, as measured using the SIB language subscale.